XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announced that its Pharmacokinetics Bridging Study – XRX-OXY-101 – Part 2 showed a significant increase in oral bioavailability of XORTX’s proprietary oxypurinol formulation provided with...
According to the World Health Organization (WHO), Coronavirus (CoV) is a family of viruses that cause illnesses ranging from common cold to lethal diseases such as the Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory Syndrome (SARS-CoV) and a new strain of CoV named, novel...
Equillium Bio (NASDAQ: EQ), a clinical–stage biopharmaceutical Company focused on bringing innovation in form of immune-modifying therapies to treat immuno-inflammatory diseases, announced the receipt of a Study May Proceed letter from the U.S Food and Drug Administration (FDA), to evaluate the company’s lead asset itolizumab,...
Fabry Disease also known as angiokeratoma corporis diffusum or alpha-galactosidase A deficiency, is an inherited disorder characterized by the buildup of globotriaosylceramide, a type of fat in the body’s cells and results in numerous disorders such as acroparesthesias (burning, tingling, or prickling sensation in extremities),...
Aurora Mobile (NASDAQ: JG), a leading developer of big data mobile solutions, announced the launch of a suite of proprietary outbreak analytic and monitoring systems aimed at monitoring and controlling the current outbreak of 2019-nCOV coronavirus, indicated for use by national ministries as well as...
Co-Diagnostics (NASDAQ: CODX), a molecular Diagnostics Company focused on developing nucleic acid molecule based reagents for diagnostic tests, announced the successful initial verification of its screening test, used for detecting the presence of the novel coronavirus. The polymerase chain reaction (PCR) screening test will soon...
Inovio Pharmaceuticals (NASDAQ: INO), a late-stage biotechnology Company developing DNA-based immunotherapies and vaccines to combat cancer and infectious diseases, announced the grant of up to $9 million by the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for Coronavirus 2019-nCoV, a deadly new...
